01—Abstract
Summary
Summary of the 10-Q filed August 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals Inc. reported solid financial results for the second quarter and first half of 2025.
Total revenues grew 12% year-over-year to $2.96 billiona for the quarter, driven by strong performance in product revenues, which increased by 11% to $2.94 billion. This growth was primarily attributed to continued demand for TRIKAFTA/KAFTRIO and the early contributions from new product launches, including ALYFTREK and JOURNAVX. The company also saw significant growth in its pipeline, with key developments in its Type 1 Diabetes, IgA Nephropathy, and Sickle Cell Disease programs.
The company reported a net income of $1.03 billionb for the quarter, a substantial turnaround from the net loss of $3.59 billion in the prior year period, which was heavily impacted by the Alpine acquisition's R&D expenses. For the six-month period, net income was $1.68 billion, compared to a net loss of $2.49 billion in the prior year.
The company's cash position remains strong, with total cash, cash equivalents, and marketable securities reaching $12.0 billionc. Management expects existing liquidity to be sufficient for at least the next twelve months, supported by ongoing operations and a robust product portfolio.
02—Key points
Key Highlights
- Total revenues for Q2 2025 increased by 12% to $2.96 billion, driven by an 11% rise in net product revenues to $2.94 billion.
- Net income for Q2 2025 was $1.03 billion, a significant improvement from a net loss of $3.59 billion in Q2 2024, largely due to the absence of large acquired R&D expenses.
- The company's strong cash position was maintained, with total cash, cash equivalents, and marketable securities reaching $12.0 billion as of June 30, 2025.
- ALYFTREK saw continued progress with new approvals and reimbursement agreements in Europe and Canada, alongside regulatory reviews in other regions.
- CASGEVY secured access for eligible patients in 10 countries, with patient infusions increasing, indicating steady commercial uptake.
- The launch of JOURNAVX in the US is progressing well, with broad payer access and inclusion in over 500 hospital formularies.
- The pipeline remains active, with completed enrollment in key Phase 3 trials for povetacicept (IgAN) and continued progress in Type 1 Diabetes (zimislecel) and APOL1-mediated kidney disease (inaxaplin).
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, Vertex Pharmaceuticals Inc kept $0.35.
- Revenue$2.96B100.0%
- Cost of revenue−$407.5M13.7%
- Gross profit$2.56B86.3%
- Operating costs−$1.41B47.4%
- Operating income$1.15B38.8%
- Interest, other & tax−$118.2M4.0%
- Net income$1.03B34.8%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 5, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $2.96B$2.65B | +12.1% |
| Cost of Revenue | $407.50M$371.90M | +9.6% |
| Gross Profit | $2.56B$2.27B | +12.5% |
| SG&A Expenses | $424.60M$372.20M | +14.1% |
| Operating Expenses | $1.81B$6.16B | −70.6% |
| Operating Income | $1.15B-$3.51B | +132.8% |
| Net Income | $1.03B-$3.59B | +128.7% |
| EPS (Basic) | $4.02$-13.92 | +128.9% |
| EPS (Diluted) | $3.99$-13.92 | +128.7% |
| Shares Outstanding (Basic) | 256.70M258.10M | −0.5% |
| Shares Outstanding (Diluted) | 258.90M258.10M | +0.3% |
05—Questions
Frequently Asked Questions
What drove the significant increase in net income from Q2 2024 to Q2 2025?
The substantial increase in net income from a loss of $3.59 billion in Q2 2024 to a profit of $1.03 billion in Q2 2025 is primarily due to the absence of a $4.4 billion acquired in-process research and development (AIPR&D) expense incurred in Q2 2024 related to the acquisition of Alpine Immune Sciences, Inc. This one-time expense heavily impacted the prior year's results.
How are the new product launches, ALYFTREK and JOURNAVX, performing?
ALYFTREK is gaining traction with new approvals and reimbursement agreements in Europe and Canada, and is under regulatory review in additional countries. JOURNAVX, the acute pain medication, has seen a successful commercial launch in the U.S., achieving broad payer access and inclusion in numerous hospital formularies, with over 110,000 prescriptions filled.
What is the company's outlook on its cash position and liquidity?
Vertex Pharmaceuticals maintains a strong liquidity position, with $12.0 billion in total cash, cash equivalents, and marketable securities as of June 30, 2025. Management expects this liquidity, combined with operating profitability, to be sufficient to fund operations for at least the next twelve months.
Are there any significant new risks or challenges highlighted in this filing?
The risk factors section indicates no material changes from previously disclosed risks. However, the company notes ongoing discussions with a third party regarding the royalty burden for ALYFTREK, where the third party's assertion differs from Vertex's interpretation of the agreement, potentially leading to a dispute. Additionally, the company is evaluating the impact of recently enacted U.S. tax legislation (H.R.1).
06—Continue